[go: up one dir, main page]

PE20170914A1 - 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa - Google Patents

1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa

Info

Publication number
PE20170914A1
PE20170914A1 PE2017000940A PE2017000940A PE20170914A1 PE 20170914 A1 PE20170914 A1 PE 20170914A1 PE 2017000940 A PE2017000940 A PE 2017000940A PE 2017000940 A PE2017000940 A PE 2017000940A PE 20170914 A1 PE20170914 A1 PE 20170914A1
Authority
PE
Peru
Prior art keywords
thioxo
pyrrolo
pyrimidin
tetrahydro
benzyl
Prior art date
Application number
PE2017000940A
Other languages
English (en)
Inventor
Tord Bertil Inghardt
Nicholas Tomkinson
Li-Ming Gan
Jeffrey Paul Stonehouse
Petra Johannesson
Ulrik Jurva
Erik Michaelsson
Eva-Lotte Lindstedt-Alstermark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20170914A1 publication Critical patent/PE20170914A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1-[2-(AMINOMETIL)BENCIL]-2-TIOXO-1,2,3,5-TETRAHIDRO-4H-PIRROLO[3,2-d]PIRIMIDIN-4-ONA DE FORMULA (I) DONDE R1 ES H, F, Cl O CF3; R2 ES H, CH3 O C2H5; R3 ES H, CH3, C2H5, ISOPROPILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-{2-[(1R)-1-AMINOPROPIL]-4-CLOROBENCIL}-2-TIOXO-1,2,3,5-TETRAHIDRO-4H-PIRROLO[3,2-d]PIRIMIDIN-4-ONA; 1-{4-CLORO-2-[1-(METILAMINO)ETIL]BENCIL}-2-TIOXO-1,2,3,5-TETRAHIDRO-4H-PIRROLO[3,2-d]PIRIMIDIN-4-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA MIELOPEROXIDASA (MPO) SIENDO UTILES EN EL TRATAMIENTO DE LA INSUFICIENCIA CARDIACA
PE2017000940A 2014-12-01 2015-11-30 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa PE20170914A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085722P 2014-12-01 2014-12-01
US201562166808P 2015-05-27 2015-05-27

Publications (1)

Publication Number Publication Date
PE20170914A1 true PE20170914A1 (es) 2017-07-12

Family

ID=54754631

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000940A PE20170914A1 (es) 2014-12-01 2015-11-30 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa

Country Status (38)

Country Link
US (5) US9616063B2 (es)
EP (1) EP3227294B1 (es)
JP (1) JP6616417B2 (es)
KR (1) KR102543404B1 (es)
CN (1) CN107001374B (es)
AU (1) AU2015357290B2 (es)
BR (1) BR112017011124B1 (es)
CA (1) CA2968449C (es)
CL (1) CL2017001380A1 (es)
CO (1) CO2017006658A2 (es)
CY (1) CY1122587T1 (es)
DK (1) DK3227294T3 (es)
DO (1) DOP2017000129A (es)
EA (1) EA030805B1 (es)
ES (1) ES2751690T3 (es)
GT (1) GT201700114A (es)
HR (1) HRP20191744T1 (es)
HU (1) HUE045606T2 (es)
IL (1) IL252436B (es)
LT (1) LT3227294T (es)
ME (1) ME03568B (es)
MX (1) MX370492B (es)
MY (1) MY195816A (es)
NI (1) NI201700065A (es)
NZ (1) NZ732164A (es)
PE (1) PE20170914A1 (es)
PH (1) PH12017500977A1 (es)
PL (1) PL3227294T3 (es)
PT (1) PT3227294T (es)
RS (1) RS59375B1 (es)
SG (1) SG11201703961UA (es)
SI (1) SI3227294T1 (es)
SM (1) SMT201900572T1 (es)
SV (1) SV2017005451A (es)
TN (1) TN2017000208A1 (es)
TW (1) TWI681963B (es)
UY (1) UY36416A (es)
WO (1) WO2016087338A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AU2018304508B2 (en) 2017-07-17 2021-06-10 Astrazeneca Ab MPO inhibitors for use in medicine
CN112151111B (zh) * 2020-08-27 2022-10-11 上海大学 基于多元线性回归快速预测黄嘌呤衍生物抑制活性的qsar方法
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
AU2023326686A1 (en) 2022-08-18 2025-04-03 Astrazeneca Ab Inhibitors of myeloperoxidase
US20240092787A1 (en) 2022-08-24 2024-03-21 Astrazeneca Ab Pharmaceutical process and intermediates
EP4580606A1 (en) 2022-08-31 2025-07-09 Astrazeneca AB Pharmaceutical formulation
CN120265633A (zh) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024209075A1 (en) * 2023-04-06 2024-10-10 Astrazeneca Ab Method of treatment with mpo inhibitors
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US20050130983A1 (en) * 2002-05-02 2005-06-16 Dae-Kee Kim Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them
SE0302756D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JP4881875B2 (ja) * 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
UY30267A1 (es) 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
JP2009533426A (ja) 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ チオキサンチン誘導体およびそれらのmpo阻害剤としての用途
CN101460501A (zh) 2006-06-05 2009-06-17 阿斯利康(瑞典)有限公司 作为髓过氧化物酶抑制剂的吡咯并[3,2-d]嘧啶-4-酮衍生物
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
CA2825599C (en) 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
MD20140044A2 (ro) 2011-11-11 2014-08-31 Pfizer Inc. 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase

Also Published As

Publication number Publication date
MY195816A (en) 2023-02-22
TN2017000208A1 (en) 2018-10-19
US9616063B2 (en) 2017-04-11
DOP2017000129A (es) 2017-09-15
CN107001374A (zh) 2017-08-01
HK1245270A1 (en) 2018-08-24
SMT201900572T1 (it) 2019-11-13
ES2751690T3 (es) 2020-04-01
US20160152623A1 (en) 2016-06-02
TWI681963B (zh) 2020-01-11
US20240335446A1 (en) 2024-10-10
MX370492B (es) 2019-12-16
US20210228585A1 (en) 2021-07-29
IL252436B (en) 2021-05-31
AU2015357290B2 (en) 2018-03-29
CL2017001380A1 (es) 2018-01-12
EP3227294B1 (en) 2019-08-14
UY36416A (es) 2016-06-01
US10016430B2 (en) 2018-07-10
CY1122587T1 (el) 2021-01-27
RS59375B1 (sr) 2019-11-29
CN107001374B (zh) 2019-06-14
EP3227294A1 (en) 2017-10-11
JP6616417B2 (ja) 2019-12-04
TW201639846A (zh) 2016-11-16
US20190076432A1 (en) 2019-03-14
MX2017007322A (es) 2018-02-19
PL3227294T3 (pl) 2020-04-30
PH12017500977A1 (en) 2017-11-27
SI3227294T1 (sl) 2019-11-29
US11000525B2 (en) 2021-05-11
US20170173025A1 (en) 2017-06-22
ME03568B (me) 2020-07-20
HUE045606T2 (hu) 2020-01-28
IL252436A0 (en) 2017-07-31
AU2015357290A1 (en) 2017-06-15
JP2017535588A (ja) 2017-11-30
SG11201703961UA (en) 2017-06-29
BR112017011124A2 (pt) 2017-12-26
DK3227294T3 (da) 2019-10-21
US11975004B2 (en) 2024-05-07
KR20170088900A (ko) 2017-08-02
CA2968449C (en) 2023-02-28
BR112017011124B1 (pt) 2022-11-16
GT201700114A (es) 2019-08-12
SV2017005451A (es) 2017-10-12
WO2016087338A1 (en) 2016-06-09
CO2017006658A2 (es) 2017-10-20
NI201700065A (es) 2018-01-04
KR102543404B1 (ko) 2023-06-14
EA201791021A1 (ru) 2017-11-30
EA030805B1 (ru) 2018-09-28
PT3227294T (pt) 2019-10-28
NZ732164A (en) 2018-02-23
CA2968449A1 (en) 2016-06-09
LT3227294T (lt) 2019-10-25
HRP20191744T1 (hr) 2019-12-27

Similar Documents

Publication Publication Date Title
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20160874A1 (es) Compuestos quimicos
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
CU20150062A7 (es) Lactamas n-(heteroarilo sustituido) fusionadas utiles en el tratamiento del crecimiento celular anormal
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20171100A1 (es) Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
CU24392B1 (es) Compuestos y composiciones para inducir condrogénesis
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
PE20150284A1 (es) Derivado de indanosulfamida novedoso
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX393092B (es) Bis-compuestos para dispositivos opticamente activos.